Prospective Study on the Feasibility and Results of POEM in Idiopathic Achalasia

Sponsor
Istituto Clinico Humanitas (Other)
Overall Status
Completed
CT.gov ID
NCT02259283
Collaborator
(none)
10
1
1
21
0.5

Study Details

Study Description

Brief Summary

Treatment options for achalasia include endoscopic dilations and surgical myotomy. Recently the POEM (Per oral endoscopic myotoymy) technique has been described. Patients undergo myotomy under endoscopic control. It has advantage over endoscopic dilation since myotomy is performed, and has advantage over surgery because it is performed endoscopically, thus is less invasive. One potential disadvantage in respect to surgery may be that it may determine higher rates of post-operative reflux. The purpose of this study is to prospectively assess the feasibility of PEOM in our Center with the new hybrid knife, and clinical results at 1, 3 and 12 months.

This is a prospective, phase II study. Ten patients (age 18-75 years old) with diagnosis of achalasia, without megaesophagus or colonic esophagus, will be included for the POEM procedure.

This study will last about 2 years. The aim is the feasibility, security and success rate of POEM for achalasia. Patients will be followed for at least one year.

Condition or Disease Intervention/Treatment Phase
  • Device: Hybrid Knife
Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Prospective Study on the Feasibility and Results of the Treatment of Idiopathic Achalasia With the POEM (Per Oral Endoscopic Myotomy) Technique
Study Start Date :
Dec 1, 2012
Actual Primary Completion Date :
Jun 1, 2014
Actual Study Completion Date :
Sep 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: Achalasia

Patients (age 18-75 years old) with diagnosis of achalasia, without megaesophagus or colonic esophagus, will undergo POEM with the hybrid knife.

Device: Hybrid Knife
POEM (Per oral endoscopic myotoymy) technique performed with the hybrid knife which combines injection and cutting in the same device.

Outcome Measures

Primary Outcome Measures

  1. Feasibility [24 months]

    Percentage of patients with successful POEM

  2. Clinical Success [24 months]

    A reduction of 2 or more points in the Eckardt score, that determines a score of 3 or more in 24 months.

Secondary Outcome Measures

  1. Quality of Life [24 months]

    Quality of life as measured by questionnaires (SF36 and l'EORTC QLQ-OES24) that will be administered to the patients at 3 and 12 months.

  2. Adverse events [24 months]

    Post-operative adverse events (perforation, bleeding, infection, aspiration, etc)

  3. Reflux disease [24 months]

    Reflux disase as diagnosed clinically (HRQL questionnarie) or by 24-hour pH-metry

  4. Treatment failure [24 months]

    Percentages of patients in which other interventions for dysphagia are required after the first POEM.

  5. Efficacy [24 months]

    Basal and post-treatment pressure of the lower esophageal sphincter, as measured by manometry and esophageal follow-through.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 18 to 75 years

  • Manometric diagnosis of achalasia

  • Eckardt score more than 3

  • Informed consent

Exclusion Criteria:
  • Increased surgical risk for important comorbidities,

  • Pseudoachalasia

  • Mega-esophagus (more than 7 cm) and or sigmoid esophagus,

  • Previous esophageal or gastric surgery (with the exception of gastric perforation)

  • Inability of completing the questionnarie

  • Inability to keep a commitment for follow-up

  • Esophageal diverticulum

Contacts and Locations

Locations

Site City State Country Postal Code
1 Endoscopy Unit, Humanitas Research Hospital Rozzano Milano Italy 20089

Sponsors and Collaborators

  • Istituto Clinico Humanitas

Investigators

  • Principal Investigator: Alessandro Repici, MD, Istituto Clinico Humanitas

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Michele Tedeschi, Chief of Clinical research Project, Istituto Clinico Humanitas
ClinicalTrials.gov Identifier:
NCT02259283
Other Study ID Numbers:
  • POEM-ICH
First Posted:
Oct 8, 2014
Last Update Posted:
Oct 8, 2014
Last Verified:
Oct 1, 2014
Keywords provided by Michele Tedeschi, Chief of Clinical research Project, Istituto Clinico Humanitas
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 8, 2014